A case report illustrates stable disease for 10 months in a BRAF-mutant epithelioid GBM patient treated with dabrafenib alone [38]; a very recently published report shows dramatic, albeit transient response to dabrafenib and trametinib in two BRAF V600E-mutant epithelioid glioblastomas [39]. The gene discussed is BRAF; the disease is glioblastoma.